Processa Pharmaceuticals Innovative Cancer Treatment Demonstrates Higher Efficacy at Lower Doses Over Capecitabine

Zinger Key Points
  • Processa highlights FDA's acknowledgment of NGC-Cap as a new chemical entity.
  • Phase 1b data shows improved safety, even with 5-FU exposure much greater than that from capecitabine.

Processa Pharmaceuticals Inc PCSA provides an interim analysis from its Phase 1b Next Generation Capecitabine (NGC-Cap) study.

Thus far in the Phase 1b study, patients have received doses of NGC-Cap ranging from 75 mg once a day to 225 mg twice daily, significantly less than the 1,600 mg to 2,500 mg twice-a-day dose administered for FDA-approved capecitabine. 

These much lower doses for NGC-Cap result in 5-FU exposure up to 10 times greater than the higher FDA-approved capecitabine doses due to NGC-Cap's unique metabolic pathway. 

5-FU comprises 5-fluorouracil, the main metabolite of capecitabine that further metabolizes into desirable cancer-killing molecules called anabolites and undesirable molecules called catabolites that cause unwanted side effects.

In addition, the side effects associated with FBAL (fluoro-beta-alanine, the primary catabolite formed from the metabolism of 5-FU), such as hand-foot syndrome, that can lead to capecitabine intolerance, were almost non-existent, likely because FBAL exposure was approximately 1% of the exposure seen after FDA-approved capecitabine administration.

The interim analysis also shows that an improvement in the side effect profile was observed at a 5-FU NGC-Cap exposure of 5-6 times greater than FDA-approved capecitabine.

These data confirm that the metabolic pathways that regulate how NGC-Cap is processed in the body suggest NGC-Cap may offer higher efficacy at lower doses of the underlying capecitabine agent, while simultaneously offering a better safety profile from less production of the side-effect producing catabolite FBAL that causes many of the dose-limiting side effects from treatment with capecitabine alone. 

It is believed that NGC-Cap's ability to inhibit the production of catabolites like FBAL is key to the success of NGC-Cap. Further clinical studies are needed to confirm these interim observations.

Price Action: PCSA shares are down 19.7% at $0.53 on the last check Tuesday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!